A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs SHR-2554 (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.
- 31 Jul 2018 New trial record